The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs
Abstract
After more than half a century of treating diabetics with animal insulins, recombinant DNA technologies and advanced protein chemistry made human insulin preparations available in the early 1980s. As the next step, over the last decade, insulin analogs were constructed by changing the structure of the native protein with the goal of improving the therapeutic properties of it, because the pharmacokinetic characteristics of rapid-, intermediate-, and long-acting preparations of human insulin make it almost impossible to achieve sustained normoglycemia. The first clinically available insulin analog, lispro, confirmed the hopes by showing that improved glycemic control can be achieved without an increase in hypoglycemic events. Two new insulin analogs, insulin glargine and insulin aspart, have recently been approved for clinical use in the United States, and several other analogs are being intensively tested. Thus, it appears that a rapid acceleration of basic and clinical research in this arena will be seen, which will have direct significance to both patients and their physicians. The introduction of new short-acting analogs and the development of the first truly long-acting analogs and the development of analogs with increased stability, less variability, and perhaps selective action, will help to develop more individualized treatment strategies targeted to specific patient characteristics and to achieve further improvements in glycemic control. Data on the currently available and tested analogs, as well as data on those currently being developed, are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739
Binder, C., Lauritzen, T., Faber, O., & Pramming, S. (1984) · Diabetes Care · doi:10.2337/diacare.7.2.188 · Cited by 341
Mudaliar, S. R., Lindberg, F. A., Joyce, M., Beerdsen, P., Strange, P., Lin, A., & Henry, R. R. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1501 · Cited by 276
Brunelle, R. L., Llewelyn, J., Anderson, J. H., Gale, E. A. M., & Koivisto, V. A. (1998) · Diabetes Care · doi:10.2337/diacare.21.10.1726 · Cited by 216
Bolli, G. B., & Owens, D. R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02546-0 · Cited by 186
Buchbinder, A., Miodovnik, M., McElvy, S., Rosenn, B., Kranias, G., Khoury, J., & Siddiqi, T. A. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.108893 · Cited by 51
Cited by
Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., & Vigneri, R. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0047 · Cited by 1,033
Insulin Receptor Isoforms in Physiology and Disease: An Updated View
Belfiore, A., Malaguarnera, R., Vella, V., Lawrence, M. C., Sciacca, L., Frasca, F., Morrione, A., & Vigneri, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00073 · Cited by 375
Cell factories for insulin production
Baeshen, N. A., Baeshen, M. N., Sheikh, A., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A. I., Saini, K. S., & Redwan, E. M. (2014) · Microbial Cell Factories · doi:10.1186/s12934-014-0141-0 · Cited by 359
Recombinant pharmaceuticals from microbial cells: a 2015 update
Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016) · Microbial Cell Factories · doi:10.1186/s12934-016-0437-3 · Cited by 339
Clinical Significance, Pathogenesis, and Management of Postprandial Hyperglycemia
Gerich, J. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.11.1306 · Cited by 321
Metadata
- Authors
- Vajo, Z., Fawcett, J., & Duckworth, W. C.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2001-10-01
- Volume
- 22
- Issue
- 5
- Pages
- 706-717
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2169013246
- Cited by
- 172
- References
- 6
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs. https://app.cochat.ai/papers/10.1210/edrv.22.5.0442
- The paper
- Vajo, Z., Fawcett, J., & Duckworth, W. C. (2001). Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs. Endocrine Reviews. https://doi.org/10.1210/edrv.22.5.0442
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.